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Open access under CC BY license.Since the advent of techniques for the expression of
recombinant peptide antigens, the availability of human
vaccines for parasitic diseases has been ‘imminent’. Yet
vaccines based on recombinant proteins are still largely
aspirations, not realities. It is now apparent that vaccine
development needs additional knowledge about host
protective immune response(s), antigen characteristics,
and the delivery required to induce those responses. The
most successful immune protection against parasites
has been generated by infection and treatment, the
induction of protective immunity by truncating the
course of an infection with drug treatment. Here, we
consider the characteristics of an effective, protective
anti-parasite vaccine and propose a conceptual frame-
work to aid parasite vaccine development using malaria
and schistosomiasis as examples.
Development of protective immune responses resulting
from infections
Exposure to pathogens allows vertebrate hosts to mount
pathogen-specific acquired immune responses that some-
times protect against subsequent infection, forming the
basis of vaccinology [1]. The original observation that pro-
tection often succeeds infection and recovery led to the
artificial inductionof immunityby infectionwithattenuated
parasites [2,3], which triggered tremendous interest in the
nature and development of naturally acquired protective
immunity and characterization of measureable markers of
immune protection. The broad range of veterinary [3] and
human [4] vaccines against bacterial and viral pathogens
are predominantly live attenuated or inactivated pathogen
formulations (Table 1). Similarly, a significant proportion of
protozoan vaccines against economically significant veteri-
nary parasites (e.g., Theileria) of livestock and companion
animals are based on inoculation with attenuated or drug
treated parasites. In humans, the most widely used ‘vacci-
nation’ for a parasitic infection is the practice of leishmani-
zation [5], where children are inoculated with parasite-
containing exudate from a cutaneous Leishmania sore in
a location typically covered by clothing. The resulting, self-
limiting lesionprovidesprotectionagainst subsequent infec-
tions that might otherwise form a disfiguring ulceration on
an exposed area. However, no vaccines against parasitic
infections are licensed for humanuse. This is at least in partCorresponding author: Mutapi, F. (fmutapi@staffmail.ed.ac.uk, wsecor@cdc.gov).
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from multiple life cycle stages, immune evasion strategies,
and use of intermediate and reservoir hosts. Unfortunately,
obtaining adequate numbers of parasites, attenuated or
otherwise, of consistent and acceptable quality to use in
vaccinations is highly challenging, as demonstrated by re-
cent studies of the Plasmodium falciparum attenuated
sporozoite vaccine (PfSPZ vaccine) in humans [6]. Never-
theless, the recent Phase 1 trial demonstrating that injec-
tion of cryopreserved P. falciparum sporozoites can be used
incontrolledhumanmalaria infectionswill greatly facilitate
this research in the future [7].
An alternative to infection with attenuated parasites is
the infection and treatment (I&T) approach where immu-
nity is induced by the release of antigens from parasitic
infections that are treated or naturally die in the host
(Figure 1). One of the most striking examples of the effect
of previous infection on subsequent protection is the rela-
tive resistance to symptomatic malaria in older children
and adults who have grown up in areas endemic for P.
falciparum. Recently, an I&T trial for malaria was per-
formed by exposing volunteers who were receiving chloro-
quine prophylaxis to P. falciparum sporozoites. The
chemoprophylaxis with sporozoites (CPS) protocol suc-
ceeded in inducing sterile immunity in all immunized
participants and wasmaintained in four of six participants
for >2 years [8]. An I&T effect is also observed in schisto-
some infections as praziquantel treatment of persons
infected with Schistosoma haematobium or Schistosoma
mansoni can induce partially protective immunity against
subsequent infections [9,10].
Another outcome of I&T is that individuals from areas
where they are likely to have been exposed to malaria or
schistosome antigens early in life tend to have a lower risk
of developing severe pathological consequences such as
cerebral malaria or hepatosplenic schistosomiasis, respec-
tively. Protectivemechanisms against pathology are poorly
understood but are hypothesized to involve induction of
different regulatory or memory immune responses. In
addition to modulation of pathology in subsequent infec-
tions, I&T effects on host immune responses are also
instructive with respect to development of defined antigen
vaccines. Most vaccine recipients in endemic areas are
likely to have had some exposure to the parasite, leading
to reactions during immunization that may differ from
those of parasite naı¨ve vaccine trial participants. ForTrends in Parasitology, March 2013, Vol. 29, No. 3 135
Table 1. Currently licensed human vaccinesa
Vaccine Common name/combination vaccine Pathogen Type of vaccine
Anthrax Bacteria Subunitb
Chicken pox Varicella Virus Live, attenuatedc
Cholera Inactivatedd
Diptheria DPT Bacteria Inactivated toxin
Haemophilus influenza type B Hib Virus Conjugatee
Hepatitis A Virus Inactivated
Hepatitis B Virus Subunit
Human papillomavirus HPV Virus Subunit
Influenza vaccine Virus Live, attenuated
Japanese encephalitis vaccine Inactivated
Measles MMR Virus Live, attenuated
Mumps MMR Virus Live, attenuated
Rubella MMR Virus Live, attenuated
Pertusis Whooping cough (DPT) Subunit
Pneumococcal infections Meningitis and pneumonia Meningococcus Bacteria Subunit
Polio Virus Inactivated
Rabies Virus Inactivated
Rotavirus Virus Live, attenuated
Small pox Virus Attenuated (Sabin polio vaccine)
Inactivated (Salk polio vaccine)
Shingles Herpes zooster Virus Live, attenuated
Tetanus DPT Bacterial toxin Inactivated toxin
Tuberculosis Bacilli Calmette–Ge´urin (BCG) bacteria Live, attenuated
Typhoid bacteria Inactivated
Yellow fever virus Live, attenuated
aTable adapted from [5] and definitions adapted from http://www.niaid.nih.gov/topics/vaccines/understanding/pages/typesvaccines.aspx.
bSubunit vaccine: a vaccine made up of only the antigens that best stimulate the immune system. They are made in one of two ways: either by chemical extraction of the
native antigen, the whole organism, or as recombinant proteins expressed in other organisms (e.g., bacteria), in which case they would be termed ‘recombinant subunit
vaccines’.
cLive attenuated vaccine: a vaccine made from the living microbe that has been weakened in the laboratory so it cannot cause disease but may still be able to replicate in the
host.
dInactivated vaccine: a vaccine made by killing the disease-causing microbe with chemicals, heat, or radiation.
eConjugate vaccine: a vaccine created by covalently attaching a poorly immunogenic antigen (e.g., a polysaccharide) to a carrier protein thereby conferring the
immunological attributes of the carrier to the attached antigen. This type of vaccine is a special type of subunit vaccine.
Review Trends in Parasitology March 2013, Vol. 29, No. 3example, the Phase I clinical trial evaluating the vaccine
against human hookworm using Ancylostoma secreted
protein (ASP-2) was discontinued when vaccination in-
duced urticarial reactions in people with pre-existing
IgE responses to ASP-2 [9]. No such adverse events have
been reported in I&T.
Similar to inoculation with attenuated parasites, I&T
has limitations that may preclude it from being a feasible
public health tool; for some parasite species, it may not be
possible to generate sufficient quantities of infectious stage
parasites to vaccinate the millions of people exposed to
these infections. Nevertheless, I&T approaches provide
key answers to some fundamental intellectual and practi-
cal questions for successful vaccine development. By con-
centrating on the principles of classical vaccination, we
describe how I&T protocols have overcome some of the
challenges of using recombinant protein immunizations.
Desirable I&T characteristics for successful vaccines
Parasites causing the greatest morbidity and disease typi-
cally induce a more or less protective immunity very
slowly. Reasons for this include poor immunogenicity of
individual antigens, poor protective immunity of major
antigens, antigenic variation (protozoa), antigen polymor-
phism, immune evasion, immunomodulation of effector
responses, and/or the requirement for a threshold amount136of antigen which is released more easily upon treatment
than from natural parasite death [10–14]. I&T approaches
have overcome some of these parasite survival strategies.
Several important characteristics that underlie their suc-
cess are discussed below.
The pathogen must be immunogenic
Parasites successfully controlled by I&T are immunogenic
during natural infections. Echinococcus granulosus oncho-
spheres provoke a high degree of protective immunity,
which is the basis of a highly effective vaccine in lambs
(90% protection [15]) and offering great potential as a
human parasite vaccine [16]. By contrast, vaccine develop-
ment against Fasciola hepatica and Fasciola gigantica is
hampered by their inability to induce immunity in their
natural hosts, even after repeated infections, suggesting
low immunogenicity of these flukes [2]. Parasites might be
immunogenic but still infect the host if the host is unable to
recognize the pathogen or mount a protective immune
response during the parasite’s immune-susceptible period.
For example, infective stages of schistosomes, filarids, and
hookworms are susceptible to immune attack but migrate
and mature before effective immune responses develop.
Subsequent infections may be prevented but only after the
initial parasites become established [17]. Furthermore,
adult schistosomes avoid the host’s protective immunity
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Figure 1. Approaches to infection and treatment vaccinations for malaria and
schistosomiasis. Vaccination by infection and treatment (I&T) against malaria is
achieved by providing chemoprophylaxis to susceptible individuals followed by
spaced treatments with sporozoites delivered by mosquito bite or needle and
syringe. Under these conditions, parasites develop in the liver but do not go
beyond early blood stage infections. After final treatment, the chemoprophylaxis is
withdrawn and individuals demonstrate increased immunity against future
challenges. Vaccination by I&T against schistosomiasis is based upon infections
acquired naturally followed by treatment with praziquantel or natural worm death,
resulting in individuals with decreased susceptibility to future exposure.
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turnover, host mimicry, andmasking themselves with host
proteins [18].
In the CPS and PfSPZ–CVac studies, the timing of drug
treatment allows full development of the liver stage para-
sites, thereby increasing the number and diversity of
parasite antigens. It also eliminates the parasites before
the onset of disease [19] and prevents inhibition of anti-
liver stage cellular immunity that would otherwise occur
during blood stage infections [20]. Additionally, with the
increased complexity of whole parasite antigens against
parasite stages for which protective immunity might not
otherwise develop, I&T offers great potential for strain-
transcending protection.
However, protozoan parasites can vary the antigens
seen by host immune systems throughmechanisms includ-
ing transcriptional and epigenetic control (in situ switch-
ing, e.g., P. falciparum orGiardia lamblia) or through gene
conversion (unidirectional recombination, e.g., Trypano-
soma brucei and Babesia bovis) [21]. I&T may overcome
antigenic variation and immune avoidance by inducing
immunity to many antigens of several parasite strains/
variants. Such broad coverage is very challenging toachieve with a recombinant vaccine, even if it is multiva-
lent, such as the AMA1 [22] or MSP-1 [23] vaccine candi-
dates. To date, antigenic switching has not been
demonstrated in helminths, although a micro-exon mech-
anism for potentially generating antigenic variation is
present in the schistosome genome [24].
Inducing protective effector, rather than regulatory
responses
Individuals infected naturally with schistosomes or
malaria parasites eventually develop effector responses
that may confer protection despite also stimulating
regulatory responses. Schistosome infection intensities
are associated with the balance between protective and
regulatory responses, which is affected by host age [25]. An
often overlooked aspect of protective immunity is how
effector responses surpass regulatory responses during
natural infection and progress to long-lived memory B
and T cells. Understanding this phenomenon may help
unlock the door to successful vaccine design.
Not all immune responses result in parasite killing or
resistance to re-infection. Indeed, some parasite evasive
mechanisms may divert the immune system to respond
against ‘decoy’ antigens. In Plasmodium, T cell mimotopes
are protein variants of parasite antigens (altered peptide
ligands) that prevent development of memory T cell effec-
tor functions of cytotoxic lymphocytes [26]. Similarly, car-
bohydrate epitopes on schistosome cercariae and egg
antigens predominantly induce IgM and IgG2 antibodies,
which are not as efficacious against schistosomulae as
other antibody subclasses [27,28] and skew the immune
system towards anergy [29]. Why the host maintains these
ineffective responses is unknown but there may be homeo-
static reasons for maintaining them [30]. Thus, the value of
these responses must be considered before disregarding
them entirely. Alternatively, certain responses may be
regulatory and suppress protective immunity, such as
the AgEm2 carbohydrate in E. granulosus that interferes
with antigen presentation and cell activation [31].
Amelioration of autoimmunity in rodents by Plasmodi-
um suggests that blood stage parasites induce immuno-
suppression. Thiswas confirmed in humans as blood stages
of P. falciparum suppress T lymphocyte reactivity to ma-
larial and unrelated antigens [32]. The several immuno-
suppressive strategies employed by Plasmodium parasites
include utilization of T cell mimotopes to inhibit T cell
activation, induce anergy, or shift the T cell phenotype [33];
alteration of antigen presentation by impairing dendritic
cell function and maturation [34]; and induction of regula-
tory T cells [35]. By contrast, the P. falciparum I&T trial in
humans resulted in equivalent or better protection than
that produced by irradiated sporozoite immunizations [36].
I&T exposes the host to all pre-erythrocytic stages, allow-
ing effector responses to be mounted against a broader
range of antigens, while limiting exposure to the patho-
genic and immunosuppressive asexual blood stages
[37,38]. In natural infections, people are typically infected
with Plasmodium from a single mosquito bite and treated
based on clinical symptoms or diagnosis, at which time the
blood stage parasites may be suppressing pre-erythrocytic
immunity. In successful Plasmodium CPS, the drug was137
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tion of sporozoites from 15 mosquitoes [39]. This require-
ment to curtail exposure to blood stage parasites for full
protection is supported by development of protective ac-
quired immunity in children receiving treatment that
restricts the development of symptomatic malaria [40].
Thus, successful vaccination must overcome the effects
of regulatory responses that are stimulated by certain
parasite life cycle stages. I&T for Plasmodium has
achieved this by minimizing immune exposure to immu-
nosuppressive blood stage parasites. How or even if this is
achieved in people who develop natural resistance to ma-
laria is unclear.
Experimental and natural helminth infections are asso-
ciated with immunoregulatory responses that polarize
CD4+ T cells towards a T helper 2 (Th2) phenotype (produc-
tion of interleukins 4, 5, and 13, secretion of IgEand IgG4 by
plasma cells, and activation of eosinophils and mast cells),
and immunosuppress worm-specific [41] and general [42]
immune responses. Helminth parasites modulate both in-
nate and adaptive arms of the immune system, targeting
both humoral and cellular responses [43]. Regulatory
responses are characterized by suppressive cytokines [in-
terleukin (IL)-10 and transforming growth factorb (TGF-b)]
produced by natural and adaptive regulatory T (Treg) cells
[44,45] that can block resistance to schistosome reinfection
in an animal model [46]. Experimental studies clearly show
thatwhilstTreg cells playan important role in shapinganti-
schistosome responses, the ‘regulatory’ arm of the immune
axis extends beyond this population [47] including other
cells such as Th1 cells and macrophages [48,49] (e.g., alter-
natively activatedmacrophages [50]). The influence of these
regulatory responses on the development of resistance in
human hosts is still under investigation. Cross-inhibition
between effector CD4+ T cell subsets (Th1, Th2, and Th17)
also means that effector cytokines [interferon (IFN)-g, IL-4,
and IL-21) are required to maintain a balanced acquired
immune response [51,52], which is associated with protec-
tive immunity against infection/re-infection [53,54]. When
schistosome infection is cleared by drug treatment, immune
reactivity can increase shortly afterwards, presumably in
response to: (i) antigen release from dead parasites [14], (ii)
reversal of hyporesponsiveness [55], or (iii) an increased
effector T (Teff):Treg ratio [56]. Thus, success of I&T in
human schistosomiasis may result partly from the treat-
ment-induced increase in effector responses relative to reg-
ulatory responses.
The effective dose: protective, non-pathological immune
responses
Quantitative studies in human schistosomiasis show that
immunosuppression alone does not explain the effects of
age on infection intensity observed in schistosome endemic
areas [57]. Rather, protective immunity develops only after
exposure surmounts a threshold of parasite immunogens
[14,58]. During natural schistosome infection, where adult
worms survive for 3–7 years [59], it may take several years
for the threshold to be reached as worm death events are
spread out over time, only occasionally exposing the host to
adult antigens that induce cross-reactive protection
against invading schistosomulae. Similarly, it may take138several rounds of Plasmodium infection for sufficient
amounts of antigens from different circulating strains of
the parasite to stimulate development of partially protec-
tive immunity [60]. In areas with higher transmission
rates, Plasmodium and schistosome infection prevalence
rates peak and decline at an earlier age. This pattern, first
described in Plasmodium in 1949 [61], and later confirmed
for other parasitic infections, is termed the ‘peak shift’ and
has been attributed to development of acquired immunity
[62]. Thus, protective immune responses develop earlier in
high rather than low transmission areas [63], possibly due
to immune stimulation after death of sufficiently large
numbers and/or strains of parasites. The greatest exposure
occurs when parasites are killed by treatment, providing in
a single event the threshold exposure seen only over time
or not at all in naturally resolving infections [64]. Prazi-
quantel treatment for schistosomiasis qualitatively and
quantitatively increases the antigens recognized by the
host’s immune system, mirroring the natural changes
observed with host age [14,64]. The complexity of an
immune response depends on the relative frequency of
antigen-specific B and T cells, the levels of antigen present,
and the period during which the antigen remains available
to antigen-presenting cells. Thus, the antigen dose is criti-
cal at several stages in the generation of a response.
Immunizationwith irradiatedP. falciparum sporozoites
or irradiated cercariae suggest that high antigen doses are
required to stimulate protective responses [65]. Further-
more, low-dose stimulation can induce antigen-specific
FOXP3+ regulatory responses in humans and promote
the development of tolerance [66]. The interaction between
the antigen dose/duration of antigen stimulation and the
immune system in humans exposed naturally to parasitic
diseases is less well studied compared with responses
induced in primary responses. An important factor in
chronic parasitic infections such as schistosomiasis is
the persistence of antigenic stimulation. In general, the
immunological outcome of persistent stimulation by low
antigen doses differs from intermittent stimulation with
high antigen doses and determines whether the outcome is
tolerance, pathology, or protection. Chronic immune acti-
vation in helminth infections results in impaired signal
transduction and anergy [67], contributing to hyporespon-
siveness [54]. I&T against schistosomiasis might overcome
this hyporesponsiveness by releasing a higher immunizing
antigen dose, thus avoiding low-dose anergy, while remov-
ing potentially immunosuppressive adult worms. Repeat-
ed treatment provides the additional necessary ‘doses’ for
improved protection by stimulating development of high-
affinity antibodies, such as anti-schistosome IgE [68].
Long-lasting induced immunity
Almost all current vaccines work through induction of
serum or mucosal antibodies that block infection or inter-
fere with invasion and proliferation. Although antibody
half-life is 30 days, effective vaccine-induced protection
persists beyond the time when antibodies should have
disappeared. Possible reasons for this include boosting
from natural infection, antigen retention in peripheral
lymph nodes by follicular dendritic cells, presence of se-
questered memory B cells in bone marrow sanctuaries, or
Review Trends in Parasitology March 2013, Vol. 29, No. 3maintenance of antigen-specific memory B cells by nonspe-
cific B cell activators or idiotypic networks. The importance
of natural boosting has been demonstrated in animal I&T
protocols for protozoa infections (e.g., Theileria [3]) and
may explain why protective immunity against parasites
can be lost when people migrate from endemic areas and
are no longer exposed [69].
Both antibodies and CD4+ T cells form crucial compo-
nents of naturally acquired protective immunity against
blood stage malaria [70]. The longevity of these responses
is a subject of much debate, with the majority of earlier
immunoepidemiological studies showing them to be short-
lived, especially in children [71–73], and characterized by a
decline in antibody titers in the absence of parasitemia
[71,74,75]. However, even in low transmission areas, P.
falciparum and Plasmodium vivax can induce long-term
protection, despite the fact that effector inflammatory
responses are short-lived [76,77]. Serum antibody titers
in low malaria transmission areas varied in breadth and
magnitude, confirming that several malaria infections are
required to induce long-lived effector responses that even
then are only partially protective. The implications of this
for vaccine development, especially for people resident in
areas of high malaria transmission, remain to be investi-
gated, and the mechanisms and generation of long-lived
responses in humans also require further investigation.
Malaria I&T provides clinical and parasitological protec-
tion against malaria for at least 2.5 years [8], compared
with the short-lived, partially protective immunity in nat-
ural infections. Furthermore, malaria I&T provided longer
lived responses than the subunit based RTS,S/AS01 for
which protection did not last beyond 12 months, particu-
larly for severe malaria [78]. Mechanistic studies of the
protective immune responses resulting from I&T will be
very informative for designing long-lasting vaccines.
Understanding the longevity of antibody responses in
schistosomiasis is confounded by the effects of repeated
infections. Long-lasting responses follow curative treat-
ment of schistosomiasis [79], which may be stimulated
by prolonged excretion of antigens from live and dead eggs
trapped in host tissues [80]. Similarly, European travelers
infected with schistosomes at a single time point had
schistosome-specific cytokine responses 8 years after treat-
ment [81]. The possibility of low-grade infection in these
participants or cross-reactivity might also explain these
observations [82]. However, it is difficult to extrapolate
these findings to endemic populations where chronic anti-
gen stimulation may result in different B and T cell dy-
namics [83].
Long-term induced immunological memory
The generation and persistence of immunological memory
after an initial encounter with a pathogen provides the
basis for subsequent protection. However, little is known
aboutmemory responses from repeated or chronic antigen
exposure. How each round of infection affects the genera-
tion and maintenance of the memory T cell pool is poorly
understood. Similar to the protective immunity in the P.
falciparum I&T trial, effector memory T cells associated
with protection against re-infection were maintained
throughout the 2.5-year follow-up period [8,19]. Bycontrast, memory effector cell responses in natural infec-
tions decline after 12 months [75]. Thus, I&T might pro-
mote the longevity of effector memory responses.
Although activation and differentiation of CD8+ and
CD4+ cells are broadly similar, vaccination strategies
designed to induce and boost different T cell memory
subsets have important distinctions. CD4+ memory T cells
require a higher antigen threshold and prolonged stimu-
lation for activation than CD8+ memory cells [84]. Also,
persistence of T cell memory after vaccination with small
viral fragments is much shorter than that achieved with
attenuated whole virus [85].This may reflect differential
temporal dynamics of memory responses and may explain
the improved performance of whole parasite vaccines or
I&T compared with recombinant vaccines. Furthermore,
attenuated sporozoite immunization may stimulate differ-
ent T cell memory generation pathways in novel sites (i.e.,
the liver) compared with natural infections, resulting in
longer lasting vaccine-induced T cell memory [86].
Long-term antigen persistence and exposure in chronic
helminth infections affects the development of immuno-
logical memory [86]. Recent work in human schistosomia-
sis showed that although there were no differences in CD8+
T cells in schistosome-infected versus uninfected people,
CD4+ T cell proportions were significantly lower in indi-
viduals with schistosomiasis [87]. The reduced memory
CD4+ cells during chronic infection may result from the
Hayflick limit (the number of times a cell will divide [88]),
which can significantly affect the generation of immuno-
logical memory under persistent antigenic stimulation
[89]. In human schistosomiasis, although praziquantel
treatment leads to a significant decline in CD4+ memory
T cell proportions, there is a pronounced increase in CD4+
memory cell replication [87]. This suggests that the nature
of immunological memory following I&T may differ from
what occurs naturally.
Concluding remarks
The biological hurdles to successful vaccine development
are clear but I&T successfully addresses many of them.
Schistosome vaccine development is hindered by factors
which include: (i) lack of vaccine candidates providing
reproducible protection in experimental models and
humans; (ii) limitations in current understanding of the
nature, development, and maintenance of protective im-
mune responses, particularly in people already exposed to
schistosomes; and (iii) how to induce protective immune
responses better and faster than what occurs naturally
while at the same time avoiding pathology or tolerance [9].
Similar hurdles face malaria vaccine development. It will
be almost 40 years from initial studies to a commercially
available formulation of RTS,S/AS01. During this time, the
scientific challenges have involved antigen identification,
identification of suitable vaccine vehicle and adjuvants,
optimization of dosage and boosting schedules, and defini-
tion of immune correlates [90]. The highly successful I&T
study with P. falciparum has provided answers to some of
these questions and the tools to answer more. The exciting
developments in I&T will hopefully provide the spring-
board for a better understanding of induced rather than
acquired immunity against parasites and offer a new139
Review Trends in Parasitology March 2013, Vol. 29, No. 3platform for development of truly effective anti-parasite
vaccines.
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